AzTrials
AzTrials

DepressionNCT01327417

Cortical/Subcortical Circuits in Late-Life Depression

An observational study of Depression, run by University of Illinois Chicago at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to examine the relationship between brain structure and depression in adults aged 60 or older. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain. Read more about this study

Who is it for?
Ages 60 years and olderHealthy volunteers can take part
Conditions the study is for
Depression
How many people
400 participants
Where
1 siteUnited States
Study dates
22 Sep 2009to Sep 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: * Geriatric Medicine and Psychiatry clinics within the UIC Medical Center. Patients with mood and other psychiatric disturbances are frequently referred by physicians from both geriatric medicine and family medicine for a consultation and sometimes for ongoing psychiatric care. * Community outreach efforts and recruitment through advertising in newsletters, local newspapers

Who may be able to join

  • Age: 60 years or greater
  • Diagnosis of major depressive disorder using standard diagnostic and statistical manual (DSM) criteria
  • Score of 15 or greater on the 17-item Hamilton Depression rating scale
  • Mini Mental Status Exam score of 24 or greater
  • No evidence of clinical dementia or any other clinical brain disorder
  • Free of psychotropic/psychoactive medications for at least 2 weeks

Who cannot join

  • Presence of dementia or any other clinical brain disorder (Parkinson's, Alzheimer's)
  • History of progressive cognitive decline and/or Mini Mental Status Exam score of less than 24
  • Lifetime diagnosis of substance abuse
  • Unstable medical illness (grade 4 on the Cumulative Illness Rating Scale)
  • Presence of any metallic implant that would preclude an MRI scan (pacemaker, etc.)
  • Concurrent Axis 1 disorder (schizophrenia, bipolar)
Show all 17Show fewer
  • Psychotropic medication implicated in depression i.e. Reserpine, Alpha methyl dopa, Beta blockers, multiple long acting benzodiazepines (valium, flurazepam, chlordiazepoxide), neuroleptics;
  • Seizure disorder
  • Stroke/Transient Ischemic Attack
  • Central nervous system disorder (Parkinson's disease, multiple sclerosis)
  • Trauma to head/Loss of Consciousness
  • Claustrophobia
  • Eating disorder (anorexia, bulimia)
  • Weight of over 350 pounds
  • Learning disorder (dyslexia, ADHD)
  • Psychosis, panic or anxiety disorder outside the context of depression
  • Mood stabilizing agents such as lithium and Divalproex sodium and antidepressants - as they have been shown to impact on brain levels of NAA, Ch and Ml

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Illinois

    Chicago, Illinois, 60612

Other trials in United States

About this study

The purpose of the study is to examine the relationship between brain structure and depression in adults aged 60 or older. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain.

Read the detailed description

Major depressive disorder (MDD) and other clinically significant forms of "minor depression" are among the most common mental disorders in the elderly. Data from the Epidemiologic Catchment Area Studies indicate that in the community dwelling elderly, the prevalence of MDD is approximately 1-2 percent. The prevalence of dysthymia and "clinically significant" depressive symptoms is estimated to be 2-3% and 5-10% respectively. Clinically significant mood disorders are responsible for considerable medical and psychosocial morbidity. These include frequent medical and psychiatric hospitalizations, visits to the emergency room, suicide attempts, and use of alcohol, and other prescription medications with psychotropic effects. The clinical impact of these disorders is comparable to those caused by other chronic medical disorders.

The vast majority of patients with mood disorders are managed at ambulatory care/primary care settings around the country. Ambulatory care clinics have become "defacto" settings for the diagnosis and management of psychiatric problems, especially in the elderly. Depression, particularly in the elderly, is associated with several chronic medical illnesses including malignancies, chronic obstructive pulmonary disease, and gastrointestinal, vascular, autoimmune and demyelinating disorders. Acknowledging the overall robust association between medical illness and mood disorders, the NIH consensus statement on depression in the elderly states, "The hallmark of depression in late-life is its association with medical comorbidity." While the precise mechanisms by which coexisting medical illnesses contribute to depression remain unclear, neuroanatomical, vascular, immunologic, psychosocial and /or a combination of these mechanisms have been invoked as possible pathways by which medical disorders may lead to depression in the elderly.

Late-life MDD is characterized by 1) Neuroanatomical changes in neocortical and subcortical regions of the brain. These principally comprise a decrease in focal brain volumes and an increase in the volume of high intensity lesions in the parenchyma; 2) The increase in high intensity lesions occurs largely, though not exclusively, in the white matter; 3) Preliminary studies suggest that there are abnormalities in white matter regions and tracts even in areas that appear normal in MR images in patients with late-life MDD when compared with controls; 4) Biochemical and biophysical changes in the white matter are likely related to the pathophysiology of major psychiatric disorders independent of the impact of cerebrovascular disease/risk factors.

TRIAL OBJECTIVES AND PURPOSE

Specific Aim 1: To estimate absolute levels and ratios (metabolite/creatine) of NAA, Ch and Ml bilaterally in the dorsolateral white matter and subcortical nuclei in patients with MDD and non-depressed controls.

Hypothesis: Absolute levels and ratios of Ch and Ml will be higher and levels of NAA will be lower in the dorsolateral white matter and the subcortical nuclei in patients with MDD when compared with controls.

Specific Aim 2: To estimate magnetization transfer ratios (MTR) bilaterally in the frontal white matter/head of the caudate nucleus and the putamen in patients with MDD and controls and to examine the relationship between MTR and MRS measures in the dorsolateral white matter. Hypothesis a: MTR will be significantly lower in normal appearing dorsolateral white matter regions and subcortical nuclei (caudate nucleus and putamen) in patients with MDD when compared with controls.

Hypothesis b: There will be an inverse relationship between MTR and normalized levels of Ml in patients diagnosed with MDD in the dorsolateral white matter bilaterally.

Specific Aim 3: To examine the neurocognitive correlates of frontal and striatal compromise identified using MRS and MT ratio measures in patients with MDD and controls. The associations between NAA and a global cognitive scale and MT ratios from the bilateral dorsolateral white matter and subcortical nuclei and subscales targeted to dorsolateral and striatal cognitive functioning will be examined.

Hypothesis a: Among healthy and depressed elderly, NAA/Cr with be positively related to a global scale of cognitive function.

Hypothesis b: Among healthy and depressed elderly, MT ratios of the dorsolateral cortices will be positively related to a subscale of dorsolateral function (working memory, executive function, nonverbal recall).

Hypothesis c: Among healthy and depressed elderly, MT ratios of subcortical nuclei will be positively related to a subscale of striatal function (processing, learning).

Exploratory analyses: In addition to the specific aims above, the investigators will conduct two three exploratory analyses.

Analysis 1: A more finely grained analysis in which the investigators examine the relationship of NAA, Ml and Cho ratios to dorsolateral and striatal subscales after examining their relationship to global cognitive function. The investigators will also study the relationship of the relative concentrations of NAA to Ml (NAA/MI) and Ch (NAA/Ch) to global and regional subscales. In addition, the preliminary MTR data suggest that there may be laterally effects, which the investigators will examine.

Analysis 2: A comparison of blood samples of the healthy versus depressed subject groups, to see if there is evidence of differences in the neurotransmitter system, hypothalamic-pituitary-adrenals (HAP) axis, and immune function between these two groups of elderly persons.

Analysis 3: To examine whether neuroimaging and cognitive measures associated with major depression are reversed by antidepressant treatment.

Conditions
Depression
Keywords
Depression
Medical subject headings
Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01327417
Study groupRoleWhat they receive
DepressedPatients with Major Depressive Disorder
Healthy ControlsNot described

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2011 (estimated)
  2. Study start22 Sep 2009
  3. Primary completion19 Aug 2014
  4. Study completionSep 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01327417
Sponsor's protocol ID
2009-0613
Other IDs
R01MH073989
Status last verified
May 2025
First submitted
30 Mar 2011
Last updated
20 May 2025
Results posted
No
Data monitoring committee
Yes

Publications

  • Ballmaier M, Narr KL, Toga AW, Elderkin-Thompson V, Thompson PM, Hamilton L, Haroon E, Pham D, Heinz A, Kumar A. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. Am J Psychiatry. 2008 Feb;165(2):229-37. doi: 10.1176/appi.ajp.2007.07030506. Epub 2007 Nov 6.

    PubMed 17986679
  • Ballmaier M, Kumar A, Elderkin-Thompson V, Narr KL, Luders E, Thompson PM, Hojatkashani C, Pham D, Heinz A, Toga AW. Mapping callosal morphology in early- and late-onset elderly depression: an index of distinct changes in cortical connectivity. Neuropsychopharmacology. 2008 Jun;33(7):1528-36. doi: 10.1038/sj.npp.1301538. Epub 2007 Aug 22.

    PubMed 17712348
  • Lavretsky H, Ballmaier M, Pham D, Toga A, Kumar A. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. Am J Geriatr Psychiatry. 2007 May;15(5):386-94. doi: 10.1097/JGP.0b013e3180325a16.

    PubMed 17463189
  • Kumar A, Ajilore O. Magnetic resonance imaging and late-life depression: potential biomarkers in the era of personalized medicine. Am J Psychiatry. 2008 Feb;165(2):166-8. doi: 10.1176/appi.ajp.2007.07111771. No abstract available.

    PubMed 18245182

Questions about this trial

What is this clinical trial studying?

An observational study of Depression, run by University of Illinois Chicago at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01327417, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Cortical/Subcortical Circuits in Late-Life Depression | AzTrials